Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: Potential physiological benefits

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Ebdrup, Bjørn H ^a   Knop, Filip K ^a   Ishøy, Pelle L ^a   Rostrup, Egill ^a   Fagerlund, Birgitte ^a   Lublin, Henrik ^a   Glenthøj, Birte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antipsychotic medication; cognition; diabetes; exenatide; GLP 1; liraglutide; neuroprotection; overweight; Schizophrenia

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; LIXISENATIDE; NEUROLEPTIC AGENT; TASPOGLUTIDE;

ARTICLE; COGNITION; DIABETES MELLITUS; DRUG EFFECT; DRUG INDUCED DISEASE; HUMAN; NEUROPROTECTION; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OBESITY; PHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84864950589     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-92     Document Type: Article

References (73)

1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008, 30:67-76. 10.1093/epirev/mxn001, 18480098.
2. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007, 298:1794-1796. 10.1001/jama.298.15.1794, 17940236.
3. Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'italien GJ, Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring) 2008, 16:749-754.
4. Due P, Heitmann BL, Sorensen TI. Prevalence of obesity in Denmark. Obes Rev 2007, 8:187-189. 10.1111/j.1467-789X.2006.00291.x, 17444960.
5. Neovius M, Janson A, Rossner S. Prevalence of obesity in Sweden. Obes Rev 2006, 7:1-3.
6. Belanger-Ducharme F, Tremblay A. Prevalence of obesity in Canada. Obes Rev 2005, 6:183-186. 10.1111/j.1467-789X.2005.00179.x, 16045630.
7. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev 2005, 6:5-7. 10.1111/j.1467-789X.2005.00165.x, 15655032.
8. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 2011, 343:d5422. 10.1136/bmj.d5422, 3172324, 21914766.
9. Herrera BM, Lindgren CM. The genetics of obesity. Curr Diab Rep 2010, 10:498-505. 10.1007/s11892-010-0153-z, 2955913, 20931363.
10. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, Jakobsen KD, Rasmussen HB, Tosato S, Rietschel M, Frank J, Owen M, Bonetto C, Suvisaari J, Thygesen JH, Pétursson H, Lönnqvist J, Sigurdsson E, Giegling I, Craddock N, O'Donovan MC, Ruggeri M, Cichon S, Ophoff RA, Pietiläinen O, Peltonen L, Nöthen MM, Rujescu D, St Clair D, Collier DA Andreassen OA, Werge T. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011, 70:59-63. 10.1016/j.biopsych.2011.01.031, 21414605.
11. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010, CD006629.
12. Tandon R, Nasrallah HA, Keshavan M. Antipsychotics, mortality and schizophrenia: What are the facts?. Schizophr Res 2011, 133:262-263.
13. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233. 10.1016/j.schres.2010.07.012, 2957510, 20692814.
14. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
15. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160:290-296. 10.1176/appi.ajp.160.2.290, 12562575.
16. Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry 2011, 33:232-237. 10.1016/j.genhosppsych.2011.03.006, 21601719.
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, , . International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity.
18. Sikorski C, Luppa M, Kaiser M, Glaesmer H, Schomerus G, König HH, Riedel-Heller SG. The stigma of obesity in the general public and its implications for public health - a systematic review. BMC Public Health 2011, 11:661. 10.1186/1471-2458-11-661, 3175190, 21859493.
19. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010, 316:104-108. 10.1016/j.mce.2009.07.008, 19628019.
20. WHO: The World Health Report : 2001 : Mental health : new understanding, new hope 2001,
21. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011, 12:131-141. 10.1111/j.1467-789X.2009.00712.x, 20122135.
22. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011, 378:815-825. 10.1016/S0140-6736(11)60814-3, 21872750.
23. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008, 34:354-366. 2632411, 18283048.
24. Jagust W. What can imaging reveal about obesity and the brain?. Curr Alzheimer Res 2007, 4:135-139. 10.2174/156720507780362146, 17430236.
25. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes Rev 2009, 10:442-455. 10.1111/j.1467-789X.2009.00570.x, 19389059.
26. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010, 35:1520-1530. 10.1038/npp.2010.21, 3055458,3055458, 20336059.
27. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009, 8:573-584. 10.1517/14740330903081725, 19538102.
28. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005, 39:479-486.
29. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, Guay DM, Romeling M, Kidwell J, Cincotta SL, Baldessarini RJ. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (Lond) 2006, 30:1011-1016.
30. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008, 299:185-193. 10.1001/jama.2007.56-b, 18182600.
31. Ben-David K, Rossidis G. Bariatric surgery: indications, safety and efficacy. Curr Pharm Des 2011, 17:1209-1217. 10.2174/138161211795656828, 21492093.
32. Gibson CD, Carnell S, Ochner CN, Geliebter A. Neuroimaging, gut peptides and obesity: novel studies of the neurobiology of appetite. J Neuroendocrinol 2010, 22:833-845. 3121301, 20553371.
33. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009, 124:44-56. 10.1016/j.pharmthera.2009.06.005, 19560488.
34. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439. 10.1152/physrev.00034.2006, 17928588.
35. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771. 10.1136/bmj.d7771, 3256253, 22236411.
36. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012, 36:890.
37. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011, 6:e25269. 10.1371/journal.pone.0025269, 3177901, 21957486.
38. Mells JE, Fu PP, Sharma S, Olson DE, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA. GLP-1 analog, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012, 302:G225-235. 10.1152/ajpgi.00274.2011, 3341115, 22038829.
39. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 2008, 103:94-103. 10.1016/j.schres.2008.05.011, 18579346.
40. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206. 10.1001/jama.298.2.194, 17622601.
41. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179. 10.1038/nm919, 12925848.
42. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011, 27:547-558. 10.1185/03007995.2010.549466, 21222567.
43. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594. 10.1523/JNEUROSCI.0529-11.2011, 21525299.
44. McClean PL, Gault VA, Harriott P, Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010, 630:158-162. 10.1016/j.ejphar.2009.12.023, 20035739.
45. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Rönnholm H, Wikström L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008, 86:326-338. 10.1002/jnr.21483, 17803225.
46. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328. 2628604, 18984744.
47. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med 1992, 327:604-612. 10.1056/NEJM199208273270905, 1640954.
48. Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006, 82:75-88. 10.1016/j.schres.2005.11.004, 16377156.
49. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006, 188:510-518. 10.1192/bjp.188.6.510, 16738340.
50. Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baaré W. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci 2010, 35:95-104. 10.1503/jpn.090049, 2834791, 20184807.
51. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, . Schizophrenia Patient Outcomes Research Team (PORT) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36:71-93. 10.1093/schbul/sbp116, 2800144, 19955390, Schizophrenia Patient Outcomes Research Team (PORT).
52. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Grieve S, Gordon E. Relationship between body mass index and brain volume in healthy adults. Int J Neurosci 2008, 118:1582-1593. 10.1080/00207450701392282, 18853335.
53. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, Uchida S, Kawashima R, Fukuda H. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring) 2008, 16:119-124.
54. Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 2006, 31:1419-1425. 10.1016/j.neuroimage.2006.01.047, 16545583.
55. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 2008, 63:652-657. 10.1002/ana.21377, 2542059, 18409192.
56. Gazdzinski S, Millin R, Kaiser LG, Durazzo TC, Mueller SG, Weiner MW, Meyerhoff DJ. BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. Obesity (Silver Spring) 2010, 18:743-748.
57. Willeumier KC, Taylor DV, Amen DG. Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults. Obesity (Silver Spring) 2011, 19:1095-1097.
58. Pinkham A, Loughead J, Ruparel K, Wu WC, Overton E, Gur R, Gur R. Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. Psychiatry Res 2011, (194):64-72.
59. Stanek KM, Grieve SM, Brickman AM, Korgaonkar MS, Paul RH, Cohen RA, Gunstad JJ. Obesity is associated with reduced white matter integrity in otherwise healthy adults. Obesity (Silver Spring) 2011, 19:500-504.
60. Kyriakopoulos M, Bargiotas T, Barker GJ, Frangou S. Diffusion tensor imaging in schizophrenia. Eur Psychiatry 2008, 23:255-273. 10.1016/j.eurpsy.2007.12.004, 18524546.
61. Maayan L, Hoogendoorn C, Sweat V, Convit A. Disinhibited eating in obese adolescents is associated with orbitofrontal volume reductions and executive dysfunction. Obesity (Silver Spring) 2011, 19:1382-1387.
62. Dazzan P, Soulsby B, Mechelli A, Wood SJ, Velakoulis D, Phillips LJ, Yung AR, Chitnis X, Lin A, Murray RM, McGorry PD, McGuire PK, Pantelis C. Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of psychosis. Schizophr Bull 2011,
63. Peters A, Bosy-Westphal A, Kubera B, Langemann D, Goele K, Later W, Heller M, Hubold C, Müller MJ. Why doesn't the brain lose weight, when obese people diet?. Obes Facts 2011, 4:151-157.
64. Siervo M, Arnold R, Wells JC, Tagliabue A, Colantuoni A, Albanese E, Brayne C, Stephan BC. Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes Rev 2011, 12:968-983. 10.1111/j.1467-789X.2011.00903.x, 21762426.
65. DelParigi A, Pannacciulli N, Le DN, Tataranni PA. In pursuit of neural risk factors for weight gain in humans. Neurobiol Aging 2005, 26(Suppl 1):50-55.
66. Benetti S, Mechelli A, Picchioni M, Broome M, Williams S, McGuire P. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 2009, 132:2426-2436. 10.1093/brain/awp098, 19420091.
67. Burger KS, Stice E. Variability in reward responsivity and obesity: evidence from brain imaging studies. Curr Drug Abuse Rev 2011, 4:182-189. 10.2174/1874473711104030182, 3462740, 21999692.
68. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthøj B. Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 2012, 71:898-905. 10.1016/j.biopsych.2012.02.007, 22418013.
69. Brinkworth GD, Buckley JD, Noakes M, Clifton PM, Wilson CJ. Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. Arch Intern Med 2009, 169:1873-1880. 10.1001/archinternmed.2009.329, 19901139.
70. Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults. ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00845507.
71. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011, 18:114-126.
72. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, CD006423.
73. Grant P, Lipscomb D, Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complications 2011, 25:244-246. 10.1016/j.jdiacomp.2011.03.002, 21601480.